Overview
Adalimumab is a fully human monoclonal antibody that targets TNF-α. Unlike infliximab, it is given as a self-administered subcutaneous injection, making it more convenient for many patients. It is approved for Crohn's disease and ulcerative colitis, as well as several other inflammatory conditions.
Key Uses
Moderate-to-severe Crohn's disease
Moderate-to-severe ulcerative colitis
Crohn's fistulising disease
Patients who prefer self-injection over clinic infusion
Also approved for rheumatoid arthritis, psoriasis, and psoriatic arthritis
How It Works
Fully human antibody that binds and neutralises TNF-α
Induction: 160 mg at week 0, 80 mg at week 2; maintenance: 40 mg every 2 weeks
Self-administered subcutaneous injection (abdomen or thigh)
Pre-filled pens and syringes available; store in refrigerator
Biosimilars (Amgevita, Hyrimoz, Hadlima) are widely available
Safety & Self-Care
Screen for TB and hepatitis B before starting
Rotate injection sites to avoid skin reactions at the same spot
Take the pen out of the refrigerator 15–30 minutes before injecting to reduce discomfort
Report any signs of infection, unusual fatigue, or new skin changes
Avoid live vaccines; keep inactivated vaccines up to date
Set a recurring reminder for every 2-week injection day
Contact Your IMCC Team
Contact your IMCC team if you develop infection signs, symptoms worsen, you are planning a pregnancy, or before any procedure or vaccination.
Share this with someone who needs it: